Japan System Techniques Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Despite higher revenue, earnings declined due to a lower gross margin and the recognition of an impairment loss, resulting in higher revenue but lower earnings. Revenue increased to ¥7.44B (+5.6% YoY), while Operating Income declined to ¥0.39B (-21.0%) and Ordinary Income fell to ¥0.40B (-21.0%). Net Income decreased substantially to ¥0.14B (-56.9%), primarily due to the one-time factor of a ¥0.16B impairment loss on fixed assets. The gross margin was 24.7%, down from the previous year, and the inability to absorb the top-line growth at the earnings level was a key feature of the current period.

Factors Behind Performance Changes

【Revenue】Revenue increased to ¥7.44B (+5.6% YoY). By segment, DXAndSI was the largest growth driver at ¥4.85B (+5.7%, 65% of total), while MedicalBigData also posted strong growth of ¥0.65B (+14.7%). Package increased to ¥1.44B (+3.3%), while Global was ¥0.51B (-1.5%), showing somewhat sluggish growth.

【Profit and Loss】Operating Income declined to ¥0.39B (-21.0%), and Ordinary Income fell to ¥0.40B (-21.0%). The gross margin declined to 24.7% from the previous year, and although the SG&A ratio improved to 19.5%, this was insufficient to absorb the decline in gross margin. Net Income deteriorated further to ¥0.14B (-56.9%), primarily due to the one-time factor of a ¥0.16B impairment loss on shared assets, recorded as an extraordinary loss, resulting in a significant divergence between Ordinary Income and Net Income. The effective tax rate was also high at 42.6%, and the limited tax effect associated with the impairment further compressed profit after tax. In conclusion, the current period resulted in higher revenue but lower earnings.

Segment Analysis

DXAndSI generated revenue of ¥4.85B (+5.7%) and Operating Income of ¥0.82B (-0.2%, margin of 16.9%), making it the Company’s leading earnings contributor and maintaining earnings almost fully despite higher revenue. Package generated revenue of ¥1.44B (+3.3%) and Operating Income of ¥0.28B (-24.8%, margin of 19.4%); although its margin remained at the highest level, profitability deteriorated. MedicalBigData posted strong revenue growth of ¥0.65B (+14.7%), but Operating Income was ¥0.03B (-40.1%, margin of 4.8%), indicating continued low profitability while the business remains in the scaling phase. Global generated revenue of ¥0.51B (-1.5%) and an Operating Loss of ¥0.05B (45.0% reduction in the loss compared with the previous year), showing an improving trend but remaining in the red. Company-wide, the stability of DXAndSI and fluctuations in the profitability of the other segments are increasing the range of movement in the overall profit margin.

Key Financial Indicators

【Profitability】The Operating Income margin declined to 5.2% from the previous year, while the Net Income margin remained at approximately 1.9%. The gross margin was 24.7%, down approximately 2.7pt from the previous year, presumably due to changes in project mix and utilization rates.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥3.50B, significantly exceeding Net Income of ¥0.14B, indicating strong cash-generation capacity. A ¥3.14B cash inflow from the decrease in trade receivables and a ¥1.29B increase in contract liabilities boosted cash flow.【Investment Efficiency】ROE was low at 0.9%, primarily due to the contraction in Net Income. Asset turnover efficiency relative to total assets showed no significant change, while financial leverage remained low and stable.【Financial Soundness】The Equity Ratio was high at 62.4%, and cash and deposits of ¥11.73B accounted for approximately 45% of total assets. Interest-bearing debt was immaterial, indicating a conservative capital structure.

Cash Flow Analysis

Operating Cash Flow was ¥3.50B, down -13.7% YoY, but still substantially exceeded Net Income of ¥0.14B, demonstrating strong cash generation. The primary factors were ¥3.14B in cash realization from the decrease in trade receivables and the accumulation of advance receipts associated with a ¥1.29B increase in contract liabilities. Billing and collection progress on projects and the recurring nature of advance receipts supported cash flow. Investing Cash Flow was a modest ¥0.02B, while capital expenditures were a minor ¥0.03B, with no large-scale investments undertaken. Financing Cash Flow was -¥0.85B, primarily reflecting cash outflows from dividend payments. As a result, free cash flow was a substantial ¥3.52B, sufficiently covering dividend payments and indicating considerable financial flexibility.

Quality of Earnings

Compared with earnings at the Ordinary Income level—Operating Income of ¥0.39B and a small positive non-operating balance of approximately ¥0.02B—Net Income for the period was significantly affected by the ¥0.16B impairment loss recorded as an extraordinary loss. The divergence from Ordinary Income of ¥0.40B to Net Income of ¥0.14B resulted from the extraordinary loss and the high effective tax rate of 42.6%, which depressed Net Income more than the change in recurring earnings power alone would suggest. Non-operating income consisted primarily of interest and dividend income and was limited to approximately 0.2% of revenue, indicating a small contribution from outside the core business. From an accrual perspective, however, OCF substantially exceeded Net Income, indicating good cash-based earnings quality. The deterioration in Net Income during the current period was significantly affected by one-time factors; from the perspective of sustainable earnings power, trends in Operating Income and Ordinary Income are more important indicators.

Earnings Forecast and Guidance

Progress against the full-year plan was 21.7% for Revenue (¥7.44B/¥34.30B), 9.4% for Operating Income (¥0.39B/¥4.15B), and 9.6% for Ordinary Income (¥0.40B/¥4.20B), below the simple one-quarter progress benchmark of 25%. Progress in Operating Income and Ordinary Income was particularly weak, reflecting the decline in gross margin and the impact of the one-time impairment loss. Neither the earnings forecast nor the dividend forecast has been revised, and management has maintained its current plan. Contract liabilities have accumulated to ¥1.79B, equivalent to approximately 24% of quarterly revenue in advance receipts, and may support revenue toward the second half of the fiscal year.

Shareholder Returns

The Company’s annual dividend forecast is ¥50, representing an increase from the previous year’s dividend of ¥11 (quarterly presentation). Based on forecast EPS of ¥119.34, the Payout Ratio is approximately 41.9%, and dividend payments of ¥0.84B are sufficiently covered by free cash flow of ¥3.52B for the current quarter. There has been no revision to the current period’s dividend forecast, and the existing plan remains unchanged. Supported by substantial cash and deposits of ¥11.73B, dividend sustainability is considered high.

Risk Factors

1. Project profitability risk: The gross margin declined to 24.7% from the previous year, and, as indicated by the deterioration in the profit margins of Package and MedicalBigData (-24.8% and -40.1%, respectively), the business structure is susceptible to the impact of changes in project mix and utilization rates.

2. Risk of recurrence of one-time losses: The Company recorded a ¥0.16B impairment loss on shared assets during the current period. If the review of the asset composition continues, additional one-time expenses may arise.

3. Segment concentration risk: DXAndSI accounts for 65% of the revenue composition, creating a structure in which demand trends and changes in the project mix in this business could have a significant impact on company-wide performance.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (it_telecom)

Profitability and Returns

Compared with the industry median, both the Operating Income margin and Net Income margin are lower, placing profitability relatively low within the industry.

Growth and Capital Efficiency

The Revenue growth rate also falls somewhat below the industry median, placing the Company’s growth speed at the lower end of the industry.

※Source: Company analysis

Key Takeaways from the Earnings Results

1. While revenue increased steadily, the decline in gross margin resulted in lower Operating Income, and the one-time impairment loss led to a substantial decrease in Net Income. The coexistence of higher revenue and lower earnings is an area requiring monitoring from a cost and profitability perspective.

2. OCF was generated at a level substantially exceeding Net Income, and cash-generation capacity supported by the accumulation of contract liabilities (advance receipts) was strong. The balance sheet was also conservative, with an Equity Ratio of 62.4%, indicating high financial soundness.

3. Progress against the full-year plan was below the standard progress benchmark of 25% for both revenue and earnings, with delays in Operating Income and Ordinary Income particularly notable. The accumulation of contract liabilities should be monitored as a factor supporting future revenue.

Theoretical Share Price (Reference Value)

Sensitivity: ¥813–¥860 at a ±1% change in the cost of equity, and ¥831–¥843 at a change of ±0.1 in ω.

Notes:

• Goodwill amortization of ¥0.8 per share has been added back to earnings (due to its non-cash nature and to improve comparability with IFRS companies).
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these values are not forecasts of the market share price or recommendations for any specific investment action, and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, where necessary, after consulting with a professional.

---End of Report---